Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Segment Information - Summary of Making Decisions Regarding the Allocation of Resources and to Assess Performance (Details)

v3.22.4
Segment Information - Summary of Making Decisions Regarding the Allocation of Resources and to Assess Performance (Details) - EUR (€)
€ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Segment Information [Line Items]      
Revenue € 983,680 € 843,920 € 662,037
Cost of sales 663,879 578,515 467,861
Gross Profit 319,801 265,405 194,176
Other operating income 18,850 9,386 5,230
Selling and Marketing expenses 26,086 20,448 20,044
Research and Development expenses 34,387 29,616 17,390
General and Administrative expenses 85,747 62,502 58,863
Operating Profit 192,431 162,225 103,109
Total assets 1,659,698 1,418,842  
Total liabilities 663,788 577,183  
External Customers      
Segment Information [Line Items]      
Revenue 983,680 843,920 662,037
Adjustments, Eliminations and Unallocated Items      
Segment Information [Line Items]      
Revenue (117,057) (70,113) (57,423)
Cost of sales (97,317) (63,393) (51,882)
Gross Profit (19,740) (6,720) (5,541)
Other operating income (148)   7
Selling and Marketing expenses 11,369 9,516 7,440
Research and Development expenses 2,676 1,886 2,254
General and Administrative expenses (2,500) (8,392) 899
Operating Profit (31,433) (9,730) (16,127)
Total assets 29,723 279,342  
Total liabilities (104,069) 77,603  
Adjustments, Eliminations and Unallocated Items | Inter-Segment      
Segment Information [Line Items]      
Revenue (117,057) (70,113) (57,423)
Biopharmaceutical and Diagnostic Solutions | Operating Segments      
Segment Information [Line Items]      
Revenue 801,237 695,172 566,027
Cost of sales 526,370 465,304 398,411
Gross Profit 274,867 229,868 167,616
Other operating income 18,985 9,386 5,193
Selling and Marketing expenses 12,287 7,736 9,762
Research and Development expenses 25,169 23,467 12,080
General and Administrative expenses 73,816 58,996 48,324
Operating Profit 182,580 149,055 102,643
Total assets 1,259,124 885,733  
Total liabilities 511,022 335,919  
Biopharmaceutical and Diagnostic Solutions | Operating Segments | External Customers      
Segment Information [Line Items]      
Revenue 799,652 694,038 564,931
Biopharmaceutical and Diagnostic Solutions | Operating Segments | Inter-Segment      
Segment Information [Line Items]      
Revenue 1,585 1,134 1,096
Engineering | Operating Segments      
Segment Information [Line Items]      
Revenue 299,500 218,861 153,433
Cost of sales 234,826 176,604 121,332
Gross Profit 64,674 42,257 32,101
Other operating income 13   31
Selling and Marketing expenses 2,430 3,196 2,842
Research and Development expenses 6,542 4,263 3,056
General and Administrative expenses 14,431 11,898 9,641
Operating Profit 41,284 22,900 16,593
Total assets 370,851 253,767  
Total liabilities 256,835 163,661  
Engineering | Operating Segments | External Customers      
Segment Information [Line Items]      
Revenue 184,028 149,882 97,106
Engineering | Operating Segments | Inter-Segment      
Segment Information [Line Items]      
Revenue 115,472 68,979 56,327
Total Segments | Operating Segments      
Segment Information [Line Items]      
Revenue 1,100,737 914,033 719,460
Cost of sales 761,196 641,908 519,743
Gross Profit 339,541 272,125 199,717
Other operating income 18,998 9,386 5,224
Selling and Marketing expenses 14,717 10,932 12,604
Research and Development expenses 31,711 27,730 15,136
General and Administrative expenses 88,247 70,894 57,965
Operating Profit 223,864 171,955 119,236
Total assets 1,629,975 1,139,500  
Total liabilities 767,857 499,580  
Total Segments | Operating Segments | External Customers      
Segment Information [Line Items]      
Revenue 983,680 843,920 662,037
Total Segments | Operating Segments | Inter-Segment      
Segment Information [Line Items]      
Revenue € 117,057 € 70,113 € 57,423